Soon Kieng Phua

Soon Kieng Phua

Auto-generated profile, based on publicly available information

Soon Kieng Phua

Department of Laboratory Medicine, Changi General Hospital, Singapore (S.-K.P., T.-C.A.).

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Hypertension
Verified
Journal Article
Open access
PDF file
NINithin R. Iyer
Nithin R. Iyer
TLThu-Thao Le
Thu-Thao Le
MKMichelle S.L. Kui
Michelle S.L. Kui
HTHak-Chiaw Tang
Hak-Chiaw Tang
CCChee-Tang Chin
Chee-Tang Chin
CCCalvin W.L. Chin
Calvin W.L. Chin
Background: The prognostic significance of focal and diffuse myocardial fibrosis in patients with cardiovascular risk factors is unclear. Methods: REMODEL (Response of the Myocardium to Hypertrophic Conditions in the Adult Population) is an observational cohort of asymptomatic patients with essential hypertension. All participants underwent cardiovascular magnetic resonance to assess for myocardial fibrosis: nonischemic late gadolinium enhancement (LGE), native myocardial T1, postcontrast myocardial T1, extracellular volume fraction including/excluding LGE regions, interstitial volume (extracellular volume×myocardial volume), and interstitial/myocyte ratio. Primary outcome was a composite of first occurrence acute coronary syndrome, heart failure hospitalization, strokes, and cardiovascular mortality. Patients were recruited from February 2016 and followed until June 2021. Results: Of the 786 patients with hypertension (58±11 years; 39% women; systolic blood pressure, 130±14 mm Hg), 145 (18%) had nonischemic LGE. Patients with nonischemic LGE were more likely to be men, have diabetes, be current smokers, and have higher blood pressure ( P <0.05 for all). Compared with those without LGE, patients with nonischemic LGE had greater left ventricular mass (66±22 versus 49±9 g/m 2 ; P <0.001), worse multidirectional strain ( P <0.001 for all measures), and elevated circulating markers of myocardial wall stress and myocardial injury, adjusted for potential confounders. Twenty-four patients had primary outcome over 39 (30–50) months of follow-up. Of all the cardiovascular magnetic resonance markers of myocardial fibrosis assessed, only nonischemic LGE (hazard ratio, 6.69 [95% CI, 2.54–17.60]; P <0.001) and indexed interstitial volume (hazard ratio, 1.11 [95% CI, 1.04–1.19]; P =0.002) demonstrated independent association with primary outcome. Conclusions: In patients with hypertension, myocardial fibrosis on cardiovascular magnetic resonance is associated with adverse cardiac remodeling and outcomes.

1 November 2020 in Clinica Chimica Acta
Verified
Journal Article
Closed access
CLC.S. Lau
C.S. Lau
HOH.M.L. Oh
H.M.L. Oh
SHS.P. Hoo
S.P. Hoo
YLY.L. Liang
Y.L. Liang
SPS.K. Phua
S.K. Phua
TAT.C. Aw
T.C. Aw

24 May 2021 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
CCChang Yin Chionh
Chang Yin Chionh
CPCheng Boon Poh
Cheng Boon Poh
DRDebajyoti M. Roy
Debajyoti M. Roy
SKSreekanth Koduri
Sreekanth Koduri
BCBing Lun Chow
Bing Lun Chow
TarChoon AwTarChoon Aw
TarChoon Aw

1 March 2021 in Practical Laboratory Medicine
Verified
Journal Article
Open access
CLC.S. Lau
C.S. Lau
SHS.P. Hoo
S.P. Hoo
YLY.L. Liang
Y.L. Liang
SPS.K. Phua
S.K. Phua
TarChoon AwTarChoon Aw
TarChoon Aw
We evaluated two SARS-CoV-2 antibody point-of-care tests (POCTs) (Abbott Panbio COVID-19 IgG/IgM and Roche SARS-CoV-2 Rapid Antibody tests) and compared the results to their respective chemiluminescent immunoassays (CLIAs) (Abbott Architect IgM, Architect IgG, Roche Cobas total antibody assays). 200 pre-pandemic sera and 48 samples positive for various conditions (18 viral hepatitis, 18 dengue, 11 ANA and 1 dsDNA) were used as controls and to assess for cross-reactivity. Anonymised residual leftover sera positive for SARS-CoV-2 on RT-PCR were recruited as cases (n ​= ​133). The sensitivity/specificity/cross-reactivity/positive predictive value (PPV)/negative predictive value (NPV) of the POCTs were assessed. Concordance between the POCTs and chemiluminescent immunoassays (CLIAs) were analysed. Abbott/Roche POCT specificity was 98.7%/100% (95% CI 96.5–99.8/98.5–100) and sensitivity was 97.2%/97.2% (95% CI 85.5–99.9/85.5–99.9) in cases ≥14 days post-first positive RT-PCR (POS), PPV was 68.7%/100% (95% CI 41.3–87.2/94.7–100.0), and NPV was 97.4%/97.6% (95% CI 97.0–97.8/97.2–98.0). In cases ≥14 days POS, concordance of Abbott/Roche POCT and CLIAs was 97.2%/100% (35/36 and 36/36 results). The sensitivity of individual IgM-band results on both POCTs did not increase >95% even after 14 days POS (Abbott 2.78%, Roche 44.4%). Both POCTs have good specificity, little cross-reactivity with other antibodies, and sensitivity >95% when used in subjects ≥14 days POS. Analysis of individual POCT IgG/IgM-bands did not provide any additional information. POCTs can substitute for CLIAs in cases ≥14 days POS. In low prevalence areas, POCTs would be especially useful when combined with antigen testing in an orthogonal format to increase the PPV of COVID-19 results.